Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleNEUROPHARMACOLOGY

The Novel 5-Hydroxytryptamine1A Antagonist LY426965: Effects on Nicotine Withdrawal and Interactions with Fluoxetine

Kurt Rasmussen, David O. Calligaro, Janet F. Czachura, Laura J. Dreshfield-Ahmad, David C. Evans, Susan K. Hemrick-Luecke, Mary Jeanne Kallman, William T. Kendrick, J. David Leander, David L. Nelson, Carl D. Overshiner, David B. Wainscott, Mary C. Wolff, David T. Wong, Theresa A. Branchek, John M. Zgombick and Yao-chang Xu
Journal of Pharmacology and Experimental Therapeutics August 2000, 294 (2) 688-700;
Kurt Rasmussen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David O. Calligaro
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Janet F. Czachura
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laura J. Dreshfield-Ahmad
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David C. Evans
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Susan K. Hemrick-Luecke
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mary Jeanne Kallman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William T. Kendrick
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. David Leander
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David L. Nelson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carl D. Overshiner
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David B. Wainscott
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mary C. Wolff
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David T. Wong
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Theresa A. Branchek
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John M. Zgombick
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yao-chang Xu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

LY426965 [(2S)-(+)-1-cyclohexyl-4-[4-(2-methoxyphenyl)-1-piperazinyl]2-methyl-2-phenyl-1-butanone monohydrochloride] is a novel compound with high affinity for the cloned human 5-hydroxytryptamine (HT)1A receptor (Ki = 4.66 nM) and 20-fold or greater selectivity over other serotonin and nonserotonin receptor subtypes. Both in vitro and in vivo studies indicate that LY426965 is a full antagonist and has no partial agonist properties. LY426965 did not stimulate [35S]guanosine-5′-O-(3-thio) triphosphate (GTPγS) binding to homogenates of cells expressing the cloned human 5-HT1A receptor in vitro but did inhibit 300 nM 5-HT-stimulated [35S]GTPγS binding with aKi value of 3.07 nM. After both p.o. and s.c. administration, LY426965 blocked the lower lip retraction, flat body posture, hypothermia, and increase in rat serum corticosterone induced by the 5-HT1A agonist 8-OH-DPAT (8-hydroxy-2-dipropylaminotetralin). In pigeons, LY426965 dose-dependently blocked the stimulus cue induced by 8-OH-DPAT but had no 8-OH-DPAT-like discriminative properties. LY426965 completely reversed the effects of nicotine withdrawal on the auditory startle reflex in rats. In microdialysis experiments, LY426965 administered together with fluoxetine significantly increased extracellular levels of serotonin above those achievable with fluoxetine alone. In electrophysiological studies, the administration of LY426965 produced a slight elevation of the firing rate of 5-HT neurons in the dorsal raphe nucleus of anesthetized rats and both blocked and reversed the effects of fluoxetine on 5-HT neuronal activity. These preclinical results indicate that LY426965 is a selective, full 5-HT1Aantagonist that may have clinical use as pharmacotherapy for smoking cessation and depression and related disorders.

Footnotes

  • Send reprint requests to: Kurt Rasmussen, Ph.D., Eli Lilly & Co., Lilly Research Laboratories, Indianapolis, IN 46285. E-mail:rasmussen_kurt{at}lilly.com

  • ↵1 Present address: Lilly Research Laboratories, Eli Lilly & Co., Indianapolis, IN 46285.

  • Abbreviations:
    5-HT
    hydroxytryptamine
    DRN
    dorsal raphe nucleus
    SSRI
    selective serotonin reuptake inhibitor
    GABA
    γ-aminobutyric acid
    GTPγS
    guanosine-5′-O-(3-thio)triphosphate
    8-OH-DPAT
    8-hydroxy-2-dipropylaminotetralin
    DMSO
    dimethyl sulfoxide
    • Received December 27, 1999.
    • Accepted April 5, 2000.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 294 (2)
Journal of Pharmacology and Experimental Therapeutics
Vol. 294, Issue 2
1 Aug 2000
  • Table of Contents
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
The Novel 5-Hydroxytryptamine1A Antagonist LY426965: Effects on Nicotine Withdrawal and Interactions with Fluoxetine
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleNEUROPHARMACOLOGY

The Novel 5-Hydroxytryptamine1A Antagonist LY426965: Effects on Nicotine Withdrawal and Interactions with Fluoxetine

Kurt Rasmussen, David O. Calligaro, Janet F. Czachura, Laura J. Dreshfield-Ahmad, David C. Evans, Susan K. Hemrick-Luecke, Mary Jeanne Kallman, William T. Kendrick, J. David Leander, David L. Nelson, Carl D. Overshiner, David B. Wainscott, Mary C. Wolff, David T. Wong, Theresa A. Branchek, John M. Zgombick and Yao-chang Xu
Journal of Pharmacology and Experimental Therapeutics August 1, 2000, 294 (2) 688-700;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleNEUROPHARMACOLOGY

The Novel 5-Hydroxytryptamine1A Antagonist LY426965: Effects on Nicotine Withdrawal and Interactions with Fluoxetine

Kurt Rasmussen, David O. Calligaro, Janet F. Czachura, Laura J. Dreshfield-Ahmad, David C. Evans, Susan K. Hemrick-Luecke, Mary Jeanne Kallman, William T. Kendrick, J. David Leander, David L. Nelson, Carl D. Overshiner, David B. Wainscott, Mary C. Wolff, David T. Wong, Theresa A. Branchek, John M. Zgombick and Yao-chang Xu
Journal of Pharmacology and Experimental Therapeutics August 1, 2000, 294 (2) 688-700;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Substituted tryptamine activity at 5-HT receptors & SERT
  • In Vivo SRI-32743 Attenuates Tat Effects on Extracellular DA
  • Kv7 Opener Attenuates Seizures and Cognitive Deficit
Show more Neuropharmacology

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics